Latest news for  (OTC:ADRDF) Stock

Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $953.00 thousand which missed the analyst consensus estimate of $1.25 million by 23.76 percent. This is a 30.89 percent decrease over sales of $1.38 million the same period last year.

Earnings

Earnings Misses

News

PGEN

Precigen Q3 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $953.00K Miss $1.25M Estimate

Billionaire Elon Musk may have been one of the central figures in the 2024 presidential election and Republican voters now view him more favorably than a year ago after Donald Trump <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">won the election.</a>
What Happened: Musk endorsed Trump in the 2024 presidential election and<a href="https://www.benzinga.com/news/24/10/41353213/tesla-ceo-elon-musk-to-campaign-for-trump-in-pennsylvania-asks-attendees-to-support-free-speech-ther"> campaigned for the president-elect </a>in the key swing state of Pennsylvania.
Since helping Trump win the 2024 election, Musk has been <a href="https://www.benzinga.com/government/regulations/24/11/41931503/trump-forms-doge-with-elon-musk-and-vivek-ramaswamy-at-the-helm-will-it-impact-tesla-ceos-role-at-the-ev-giant-and-spacex">named to lead</a> the Department of Government Efficiency, or D.O.G.E for short, alongside Vivek Ramaswamy.
Musk will likely play a central role in the Trump administration going forward and it comes as Republicans have a more favorable opinion of the billionaire.
A Morning Consult <a href="https://pro.morningconsult.com/analysis/elon-musk-trump-administration-influence">poll </a>conducted on Nov. 6 and Nov. 7 after Trump won the election found that 72% of Republicans had a favorable view of Musk, up from 52% a year ago. The poll found that 17% of Republican had an unfavorable view of Musk. The remaining respondents said they had heard of Musk and had no opinion (10%) or had never heard of Musk (1%).
For comparison, here is how Musk's favorable and unfavorable ratings compare to other key Republican figures. The following are the percent of Republican voters who said they viewed each person favorable or unfavorable:
<ul>
<li>Donald Trump: 87% favorable, 11% unfavorable</li>
<li>Republicans in Congress: 83% favorable, 12% unfavorable</li>
<li>J.D. Vance: 74% favorable, 12% unfavorable</li>
<li>Mike Johnson: 39% favorable, 14% unfavorable</li>
<li>Mitch McConnell: 29% favorable, 37% unfavorable</li>
</ul>
The poll shows Musk's favorable rating ranking nearly the same as vice-president-elect Vance. Musk also is viewed more favorable by Republicans than that of Speaker of the House Johnson and current Senate Minority Leader McConnell.
Musk does have the second worst unfavorable rating at 17%, ranking only ahead of McConnell, who has often clashed with Trump and members of his own party.
The poll also found that 53% of Republicans said Musk should play "a major role" in the Trump administration moving forward. This ranked ahead of Robert F. Kennedy Jr., who saw 49% of Republican voters say he should play a major role moving forward.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk is viewed much more favorably by Republican voters than Democrats and Independent voters according to the latest poll.
The poll found that Democratic voters view Musk more unfavorable (71%) than favorable (17%). This is a big change from a year ago when Musk had a favorable rating of 32% and unfavorable rating of 46% from Democratic voters.
Independent voters are also more likely to have an unfavorable view of Musk (48%) than a favorable one (36%). This is a change from a year ago when 40% had unfavorable views of Musk and 34% viewed him favorable.
Overall, Musk had a favorable rating of 42% and unfavorable rating of 45% across all voters, compared to 40% favorable and 36% unfavorable a year ago.
Morning Consult has conducted the poll asking for views on Musk four times based on the latest poll, with results coming for April 2022, June 2022, November 2023 and November 2024.
Musk had his highest overall favorable rating of 45% from all voters back in April 2022.
While Musk's favorable rating is up to 72% and his unfavorable rating was down compared to a year ago amongst Republican voters, Musk had a lower unfavorable rating from Republican voters of 13% back in April 2022.
One of the key questions moving forward is if Musk's support of Trump, who has been a vocal critic of electric vehicles will hurt Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Based on the surging price of Tesla stock since the 2024 election, Tesla investors see a Trump win as a positive with shares up 14.8% on the day after the election. Tesla stock is up 24.6% since the closing price on Election Day.
Trump's win could see the end of federal credits for electric vehicles, which could be negative for the sector. Tesla may not lose as much as the company is profitable and has large scale compared to electric vehicle competitors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/41887136/snl-parodies-elon-musk-and-donald-trump-after-2024-election-billionaire-says-show-is-out-of-touch-with-reality">SNL Parodies Elon Musk And Donald Trump After 2024 Election: Billionaire Says Show Is &#8216;Out Of Touch With Reality&#8217;</a></li>
</ul>
Image: Shutterstock

Politics

TSLA

Elon Musk's Favorability With GOP Voters Nearly As High As J.D. Vance: How Views Of Billionaire Changed Among Political Parties

Chardan Capital analyst Keay Nakae downgrades Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

ALUR

Chardan Capital Downgrades Allurion Technologies to Neutral

Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.35) by 66.67 percent. The company reported quarterly sales of $328.400 million which beat the analyst consensus estimate of $16.400 million by 1.90K percent. This is a 60.35 percent increase over sales of $204.800 million the same period last year.

Earnings Beats

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Hldgs Q3 2024 GAAP EPS $(0.45) Beats $(1.35) Estimate, Sales $328.400M Beat $16.400M Estimate

Financing

XCUR

Exicure Enters Into Purchase Agreements For $1.3M And $8.7M Equity Financing

Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.67) by 76.05 percent. The company reported quarterly sales of $5.863 million which missed the analyst consensus estimate of $6.000 million by 2.28 percent. This is a 218.30 percent increase over sales of $1.842 million the same period last year.

SYTA

Siyata Mobile Q3 2024 GAAP EPS $(0.40) Beats $(1.67) Estimate, Sales $5.863M Miss $6.000M Estimate

Exicure Q3 EPS $(0.57) Up From $(3.04) YoY

WIIM

ADGM

Adiago Medical Holdings shares are trading after the company reported better-than-expected Q3 financial results.

Contracts

AXON

Axon Wins Federal Government Contract To Supply Royal Canadian Mounted Police With Body-Worn Cameras; Terms Not Disclosed

Outlook
Post management expects Adjusted EBITDA for fiscal year 2025 to be between $1,410-$1,460 million. Post management expects fiscal year 2025 capital expenditures to range between $380-$420 million, which includes Post Consumer Brands investment in network optimization and pet food safety and capacity, for aggregate expenditures of $90-$100 million. This also includes Foodservice investment in the completion of the Norwalk, Iowa precooked egg facility expansion and continued cage-free egg facility expansion, for aggregate expenditures of $80-$90 million.
Post provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted EBITDA non-GAAP guidance measure to the most directly comparable GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for income/expense on swaps, net, gain/loss on extinguishment of debt, net, integration and transaction costs, mark-to-market adjustments on commodity and foreign exchange hedges, mark-to-market adjustments and impairments on equity securities and investments, equity method investment adjustment and other charges reflected in Post's reconciliations of historical numbers, the amounts of which, based on historical experience, could be significant. For additional information regarding Post's non-GAAP measures, see the related explanations presented under "Use of Non-GAAP Measures."

Guidance

POST

Post Management Expects Adjusted EBITDA For FY25 To Be Between $1.410B-$1.460B; Capital Expenditures To Range Between $380M-$420M

BRLS

Borealis Foods Q3 EPS $(0.23) Up From $(0.61) YoY, Net Revenue $7.69M Down From $7.72M YoY

LGCY

Legacy Education Q1 EPS $0.21 Up From $0.11 YoY: Revenue $14.005M Up From $10.366M YoY

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

Price Target

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

Post Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.23 by 24.39 percent. This is a 6.13 percent decrease over earnings of $1.63 per share from the same period last year. The company reported quarterly sales of $2.01 billion which beat the analyst consensus estimate of $1.97 billion by 2.29 percent. This is a 3.34 percent increase over sales of $1.95 billion the same period last year.

Post Hldgs Q4 Adj $1.53 Beats $1.23 Estimate, Sales $2.01B Beat $1.97B Estimate

CEA Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEAD#NASDAQ">CEAD</a>) reported quarterly losses of $(0.94) per share. This is a 21.67 percent increase over losses of $(1.20) per share from the same period last year. The company reported $391.00 thousand in sales this quarter. This is a 57.20 percent decrease over sales of $913.57 thousand the same period last year.

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CEA Industries Q3 EPS $(0.94) Up From $(1.20) YoY, Sales $391.00K Down From $913.57K YoY

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Equities

Government

Regulations

Health Care

Markets

Movers

MRNA

NVAX

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

Trading Ideas

BRK/A

FWONA

FWONK

SIRI

Berkshire Hathaway 13F Shows Exited Position In Liberty Media Corp Series C, Previously Holding 70M Shares, Worth $1.55B; Exited Position In Liberty Media Corp Series A, Previously Holding 35.18M Shares, Worth $779.3M; Exited Position In Floor & Decor Holdings, Previously Holding 3.98M Shares, Worth $395.4M; Exited Position In Sirius XM Holdings Inc, Previously Holding 132.88M Shares, Worth $376M

NVFY

Nova Lifestyle shares are trading higher after the company announced better-than-expected Q3 financials.

TSSI

TSS Q3 EPS $0.10 Up From $0.01 YoY; Revenue $70.068M Up From $8.880M YoY

Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.08) by 175 percent. This is a 26.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $64.52 million which missed the analyst consensus estimate of $68.61 million by 5.97 percent. This is a 2.60 percent decrease over sales of $66.24 million the same period last year.

FLNT

Fluent Q3 Adj $(0.22) Misses $(0.08) Estimate, Sales $64.52M Miss $68.61M Estimate

Comments

News

Latest news for (OTC:ADRDF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga